Q-omics provides the consensus-scored GCM2 profile across patient tissues and cancer cell-line models. GCM2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, GCM2 is differentially expressed in 3, with the highest sampling consensus in UCEC. Additionally, GCM2 RNA expression shows 14,091 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, UCEC, and THYM as cancer lineages where GCM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCM2 survival associations across molecular data types. GCM2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCM2 RNA expression–survival associations across cancer types. High GCM2 expression shows unfavorable associations in CESC, THCA, KIRC, MESO and SARC, but favorable associations in UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for GCM2 RNA expression.
This table summarizes GCM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for GCM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCM2 shows lower tumor expression in UCEC and KIRP and higher tumor expression in BLCA. The UCEC box plot shows higher GCM2 RNA expression in normal versus tumor tissue (log2 FC = −0.070, t-test p = .023).
This table shows molecular features associated with GCM2 in patient tissues and cancer cell lines. In patient samples, GCM2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GCM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
